Circulating enterolactone and risk of endometrial cancer.
It has been suggested that phytoestrogens protect against hormone-dependent cancers. Lignans are the main class of phytoestrogens in Western diets. We conducted a prospective study of endometrial cancer and circulating levels of the main human lignan, enterolactone. The design was a case-control study nested within 3 prospective cohort studies, in New York, Sweden and Italy. Serum or plasma samples had been collected at enrollment and stored at -80 degrees C. A total of 153 cases, diagnosed a median of 5.3 years after blood donation, and 271 matched controls were included. No difference in circulating enterolactone was observed between cases (median, 19.2 nmol/L) and controls (18.5 nmol/L). Adjusting for body mass index, the odds ratio for the top tertile of enterolactone, as compared to the lowest was 1.2 (95% CI, 0.7-2.0; p for trend = 0.53). Lack of association was observed in both pre- and postmenopausal women. No correlation was observed between enterolactone and circulating estrogens or SHBG in healthy postmenopausal women. These results do not support a protective role of circulating lignans, in the range of levels observed, against endometrial cancer.
Zeleniuch-Jacquotte
Anne
A
Department of Environmental Medicine, New York University School of Medicine, New York, NY 10016-3240, USA. anne.jacquotte@med.nyu.edu
Lundin
Eva
E
Micheli
Andrea
A
Koenig
Karen L
KL
Lenner
Per
P
Muti
Paola
P
Shore
Roy E
RE
Johansson
Ingegerd
I
Krogh
Vittorio
V
Lukanova
Annekatrin
A
Stattin
Pär
P
Afanasyeva
Yelena
Y
Rinaldi
Sabina
S
Arslan
Alan A
AA
Kaaks
Rudolf
R
Berrino
Franco
F
Hallmans
Göran
G
Toniolo
Paolo
P
Adlercreutz
Herman
H
D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000097:blood; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D016889:Endometrial Neoplasms / Q000097:blood*; D005260:Female; D006801:Humans; D007558:Italy; D017705:Lignans / Q000097:blood*; D008875:Middle Aged; D009518:New York; D016017:Odds Ratio; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013548:Sweden
D014408:Biomarkers, Tumor; D017705:Lignans; D015107:4-Butyrolactone; C029497:2,3-bis(3'-hydroxybenzyl)butyrolactone